Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05847608
Other study ID # B2023:018
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date June 2023
Est. completion date December 2024

Study information

Verified date April 2023
Source University of Manitoba
Contact Stephen Cornish, PhD
Phone 204-474-9981
Email stephen.cornish@umanitoba.ca
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to test omega-3 fatty acid supplementation as a treatment in adolescents with a concussion. The main questions it aims to answer are: - Does supplementing with omega-3 fatty acids improve time to recovery following sport related concussion. - Does supplementing with omega-3 fatty acids improve health related quality of life following concussion. - Does supplementing with omega-3 fatty acids change post-concussion symptoms following concussion. - Does supplementing with omega-3 fatty acids change saliva concentrations of interleukin-6 following concussion. - Does supplementing with omega-3 fatty acids change saliva concentrations of cortisol following concussion. Participants will be randomized to receive either an omega-3 supplement or placebo after they have been diagnosed with a concussion. Researchers will compare the omega-3 supplement group and placebo group to see if omega-3 fatty acids, consumed as a treatment, can improve time to recovery, health related quality of life and symptom burden, and whether omega-3 fatty acids alter interleukin-6 and cortisol concentrations in saliva following a concussion.


Description:

Following mild traumatic brain injury, a neurometabolic cascade occurs with concurrent neuronal disruptions, metabolic changes, excitotoxicity, and changes in cerebral blood flow. Omega-3 fatty acids have been postulated as a possible nutritional supplement which could aid in recovery following a concussion. The omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are derived from alpha-linolenic acid (ALA) which is an essential fatty acid. DHA is present at high concentrations in neuronal cells and contributes to the regulation of cell membranes, neurotransmitter release, neurogenesis, and neuroinflammation. EPA is converted to E-series resolvins which act in an anti-inflammatory manner. Pre-clinical research supports the potential benefits of omega-3 fatty acids following a TBI. There has recently been one pilot study in human adolescents which also supports the need for large randomized controlled trials to fully understand the impact omega-3 fatty acids may have on recovery following concussion. The current evidence suggests that omega-3 supplementation may ameliorate neuroinflammation and neuronal apoptosis, and decrease reactive oxygen species associated with TBI. It has been suggested that following TBI, omega-3 supplementation may improve neural plasticity and signaling related molecules which can improve cognitive function following TBI. Based on these previous mentioned studies it appears that omega-3 fatty acids could potentially benefit those recovering from a concussion. However, to date there have not been any appropriately powered randomized controlled trials evaluating the efficacy of omega-3 supplementation following sport related concussion.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 140
Est. completion date December 2024
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 14 Years to 17 Years
Eligibility Inclusion Criteria: 1. Provide a signed and dated informed consent form; 2. State their willingness to comply with all study procedures and availability for the duration of the study; 3. Be between 14 and 17 years of age or older; 4. Meet the diagnostic criteria of a concussion set forth by the Consensus Statement on Concussion in Sport 5th Annual Conference of Concussion in Sport, 2017 as determined by the treating physician; 5. Present with a sport related concussion within 7 days from injury; and 6. Assigned a Glasgow coma scale (GCS) score = 15. Exclusion Criteria: 1. Patients with a history of moderate or severe traumatic brain injury, epilepsy, or stroke; 2. Patients who have been diagnosed with a skull fracture, traumatic subarachnoid hemorrhage, subdural hematoma, epidural hematoma, intraparenchymal hemorrhage or cerebral contusion on previous neuro-imaging studies; 3. Pregnant patients; 4. Patients with a GCS score less than or equal to 14; 5. Patients for whom parental/guardian consent cannot be obtained; 6. Patients who have consumed an omega-3 fatty acid containing supplement within the past month; 7. Patients with a fish or shell fish allergy.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Omega-3
Daily consumption of 500 mg DHA and 750 mg EPA in liquid form
Placebo
Oleic Acid, Linoleic Acid

Locations

Country Name City State
Canada Applied Research Centre, Faculty of Kinesiology, University of Manitoba Winnipeg Manitoba

Sponsors (1)

Lead Sponsor Collaborator
University of Manitoba

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to clinical recovery Time to clinical recovery will be determined by the patients treating physician. This will be defined as: 1) symptoms have returned to baseline or resolved, 2) normal medical examination, 3) tolerating school full-time without symptoms, and 4) tolerating appropriate return to play steps and are cleared to participate in full sport activities. Maximum of 6 weeks
Secondary Pediatric Quality of Life Inventory (Version 4.0) Teen Report Participants will complete the paediatric quality of life inventory (https://www.pedsql.org/index.html) each week until the participant is determined to be clinically recovered or have not recovered by 6 weeks. Scale minimum score is 0 and maximum is 52. Higher scores mean worse outcome. Maximum of 6 weeks
Secondary Pediatric Quality of Life Inventory (Version 4.0) Parents Report Parent/guardian will complete the paediatric quality of life inventory (https://www.pedsql.org/index.html) each week until the participant is determined to be clinically recovered or have not recovered by 6 weeks. Scale minimum score is 0 and maximum is 52. Higher scores mean worse outcome. Maximum of 6 weeks
Secondary Sport Concussion Assessment Tool - 5 Symptom Evaluation Participants will report their symptoms using the post-concussion symptom scale ((PCSS; version from the Sport Concussion Assessment Tool-5) each week until they are determined to be clinically recovered or have not recovered by 6 weeks. Scale minimum score is 0 and maximum is 132. Higher scores mean worse outcome. Maximum of 6 weeks
Secondary Interleukin-6 Interleukin-6 will be analyzed via enzyme-linked immunosorbent assay (ELISA) to determine changes in inflammatory status. Maximum of 6 weeks
Secondary Cortisol Cortisol will be analyzed via enzyme-linked immunosorbent assay (ELISA) to determine changes in stress status. Maximum of 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05849064 - Concussion Treatment in Older Adults N/A
Terminated NCT04586179 - A Comparison Between Cardiovascular Exercise Modes Following Sport Related Concussion N/A
Not yet recruiting NCT05943561 - Biomarkers in Concussion
Completed NCT03236389 - Brain Dynamics in Response to Jugular Vein Compression N/A
Completed NCT02721537 - Use of 31P MRS to Assess Brain NAD+ in Healthy Current and Former Collegiate Athletes N/A
Completed NCT01832714 - Assessment of Oculomotor, Vestibular and Reaction Time Response Following a Concussive Event
Completed NCT04560400 - Reverse King-Devick Test and History of Multiple Concussions N/A
Completed NCT03678077 - Trends in Cohabitation Status, Academic Achievement and Socio-economic Indicators After Mild Traumatic Brain Injury
Recruiting NCT05262361 - Persistent Post-Concussion Symptoms With Convergence Insufficiency N/A
Recruiting NCT05105802 - Mindfulness-Based Intervention for Mild Traumatic Brain Injury N/A
Terminated NCT03123822 - Spectacles Lens in Concussed Kids N/A
Completed NCT04641832 - The Combined Effect of Chronic Cannabis Use and Subconcussive Head Impacts on Brain Health N/A
Completed NCT04074486 - Evaluation and Validation of a Multimodal Brain Function Biomarker With NPC
Withdrawn NCT04578743 - Exercise as Concussion Therapy Trial- 2 Phase 2
Completed NCT03170856 - The Effects of a Sub-maximal Exercise Program on Adolescents Who Sustained a Concussion N/A
Completed NCT03671083 - Validation of Brain Function Assessment Algorithm for mTBI/Concussion
Completed NCT05069948 - Delivery of Digital Cognitive Behavioural Therapy Following Concussion N/A
Recruiting NCT03889483 - Neurophysiological Measurements Using the NeuroCatchâ„¢ Platform in Pediatric Concussion N/A
Withdrawn NCT02959294 - Use of Adipose-Derived Stem/Stromal Cells in Concussion and Traumatic Brain Injuries Early Phase 1
Recruiting NCT06093295 - Non-invasive Brain Stimulation and Injury Risk Biomechanics N/A